3 Indian Pharmaceuticals to manufacture Remdesivir |
U.S. drug-maker Gilead Sciences has signed non-exclusive voluntary licensing agreements with three Indian pharmaceutical companies — Cipla, Hetero Labs and Jubilant Life Sciences – who will manufacture and sell the anti-viral drug Remdesivir to treat severe COVID-19 patients. Gilead`s Remdesivir has received emergency use authorization from the U.S. Food and Drug Administration for the treatment of hospitalized patients with severe COVID-19 symptoms. Two other drug manufacturers – U.S.-based Mylan, which has a strong base in India, and Pakistan-based Ferozsons Laboratories – have also signed licensing agreements with Gilead, which negotiated long-term voluntary licenses with several generic drug makers in India and Pakistan to produce Remdesivir for developing countries. Hetero, which has been working with the ICMR for necessary approvals, said Remdesivir would be manufactured at its formulation facility in Hyderabad. Cipla will be permitted to manufacture the active pharmaceutical ingredient and finished product, and market it in 127 countries, including India and South Africa under Cipla`s own brand name. The health ministry is examining Remdesivir, which was used during the Ebola outbreak, as one protocol in the treatment for Covid-19 in the country.
|
|
|
|